Thrombopoietin/THPO Antibody (1053909) [Unconjugated]

Thrombopoietin/Tpo was detected in immersion fixed paraffin-embedded sections of breast cancer using Mouse Anti-Human Thrombopoietin/Tpo Monoclonal Antibody (Catalog # MAB2882) at 5 µg/mL for 1 hour at room temperature followed by incubation with the Anti-Mouse IgG VisUCyte™ HRP Polymer Antibody (Catalog # VC001). Before incubation with the primary antibody, tissue was subjected to heat-induced epitope retrieval using VisUCyte Antigen Retrieval Reagent-Basic (Catalog # VCTS021). Tissue was stained using DAB (brown) and counterstained with hematoxylin (blue). Specific staining was localized to cytoplasm and cell surface of cancer cells. View our protocol for IHC Staining with VisUCyte HRP Polymer Detection Reagents.

• Reactivity: Hu
• Applications: IHC
• Clone: 1053909
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Unconjugated

Thrombopoietin/THPO Antibody (1053909) [Unconjugated] Summary

• Immunogen: Mouse myeloma cell line, NS0-derived human Thrombopoietin/Tpo protein
  Ser22-Gly353
  Accession # P40225
• Specificity: Detects human Thrombopoietin/Tpo in direct ELISA.
• Source: N/A
• Isotype: IgG1
• Clonality: Monoclonal
• Host: Mouse
• Purity Statement: Protein A or G purified from ascites

Applications/Dilutions

• Dilutions:
  • Immunohistochemistry 5-25 ug/mL

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
• Reconstitution Instructions: Reconstitute at 0.5 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Thrombopoietin/THPO Antibody (1053909) [Unconjugated]

• Megakaryocyte colony-stimulating factor
• Megakaryocyte growth and development factor
• megakaryocyte stimulating factor
• MGDF
• MGDFC-mpl ligand
• MKCSF
• MK-CSF
• ML
• MPL ligand
• MPLLG
• MPLLGMGC163194
• Myeloproliferative leukemia virus oncogene ligand
• THCYT1
• THPO
• thrombopoietin nirs variant 1
• Thrombopoietin
• Tpo
• TPOMKCSF

Background

Thrombopoietin (Tpo), is a key regulator of megakaryocytopoiesis and thrombopoiesis. It is principally produced in the liver and is bound and internalized by the receptor Tpo R/c-mpl. Defects in the Tpo-Tpo R signaling pathway are associated with a variety of platelet disorders (1 - 3). The 353 amino acid (aa) human Tpo precursor is cleaved to yield the 332 aa mature protein. Mature human Tpo shares approximately 70% aa sequence homology with mouse and rat Tpo. It is an 80 - 85 kDa protein that consists of an N-terminal domain with homology to Erythropoietin (Epo) and a C-terminal domain that contains multiple N-linked and O-linked glycosylation sites (4, 5). Tissue specific alternate splicing of human Tpo generates multiple isoforms with internal deletions, insertions, and/or C-terminal substitutions (6). Tpo promotes the differentiation, proliferation, and maturation of megakaryocytes (MK) and their progenitors (4, 5, 7). Several other cytokines can promote these functions as well but only in cooperation with Tpo (8, 9). Notably, IL-3 independently induces MK development, although its effects are restricted to early in the MK lineage (8, 9). Tpo additionally promotes platelet production, aggregation, ECM adhesion, and activation (10 - 13). It is cleaved by platelet-derived thrombin following Arg191 within the C-terminal domain and subsequently at other sites upon extended digestion (14). Full length Tpo and shorter forms circulate in the plasma (4, 5). The C terminal domain is not required for binding to Tpo R or inducing MK growth and differentiation (5). Aside from its hematopoietic effects, Tpo is expressed in the brain where it promotes the apoptosis of hypoxia-sensitized neurons and inhibits neuronal differentiation by blocking NGF induced signaling (15, 16).

1. Deutsch, V.R. and A. Tomer (2006) Br. J. Haematol. 134:453.
2. Kaushansky, K. (2005) J. Clin. Invest. 115:3339.
3. Li, J. et al. (1999) Br. J. Haematol. 106:345.
4. Bartley, T.D. et al. (1994) Cell 77:1117.
5. de Sauvage, F.J. et al. (1994) Nature 369:533.
6. Marcucci, R. and M. Romano (2008) Biochim. Biophys. Acta 1782:427.
7. Kaushansky, K. et al. (1994) Nature 369:568.
8. Kaushansky, K. et al. (1995) Proc. Natl. Acad. Sci. 92:3234.
9. Broudy, V.C. et al. (1995) Blood 85:1719.
10. Lok, S.I. et al. (1994) Nature 369:565.
11. Chen, J. et al. (1995) Blood 86:4054.
12. Oda, A. et al. (1996) Blood 87:4664.
13. Van Os, E. et al. (2003) Br. J. Haematol. 121:482.
14. Kato, T. et al. (1997) Proc. Natl. Acad. Sci. 94:4669.
15. Ehrenreich, H. et al. (2005) Proc. Natl. Acad. Sci. 102:862.
16. Samoylenko, A. et al. (2008) Cell. Signal. 20:154.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Bioinformatics

• Uniprot:
  • P40225()